HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print September 12, 2006

This Article Full Text (Reprint (PDF)) All Versions of this Article: jlb.0306169v1 81/1/75    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ito, N. Articles by Lotze, M. T. Search for Related Content PubMed PubMed Citation Articles by Ito, N. Articles by Lotze, M. T.

© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0306169

Received for publication March 5, 2006.
Revised August 1, 2006.
Accepted for publication August 2, 2006.

Article

Cytolytic cells induce HMGB1 release from melanoma cell lines

Norimasa Ito ^*, Richard A. DeMarco ^*, Robbie B. Mailliard ^*, Jie Han , Hannah Rabinowich , Pawel Kalinski ^*, Donna Beer Stolz , Herbert J. Zeh III^*, and Michael T. Lotze ^*@

Departments of *Surgery, Pathology, and Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pennsylvania

^@ To whom correspondence should be addressed. E-mail: lotzemt{at}upmc.edu.

	Abstract

High mobility group box 1 (HMGB1) is one of the recently defined damage-associated molecular pattern molecules, passively released from necrotic cells and secreted by activated macrophage/monocytes. Whether cytolytic cells induce HMGB1 release from tumor cells is not known. We developed a highly sensitive method for detecting intracellular HMGB1 in tumor cells, allowing analysis of the type of cell death and in particular, necrosis. We induced melanoma cell death with cytolytic lymphokine-activated killing (LAK) cells, tumor-specific cytolytic T lymphocytes, TRAIL, or granzyme B delivery and assessed intracellular HMGB1 retention or release to investigate the mechanism of HMGB1 release by cytolytic cells. HMGB1 release from melanoma cells (451Lu, WM9) was detected within 4 h and 24 h following incubation with IL-2-activated PBMC (LAK activity). HLA-A2 and MART1 or gp100-specific cytolytic T lymphocytes induced HMGB1 release from HLA-A2-positive and MART1-positive melanoma cells (FEM X) or T2 cell-loaded, gp100-specific peptides. TRAIL treatment, however, induced HMGB1 release, and it is interesting that this extrinsic pathway-mediated cell death was blocked with the pancaspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. Conversely, granzyme B delivery did not induce HMGB1 release. HMGB1, along with other intracellular factors released from tumor cells induced by cytolysis, may be important components of the disordered tumor microenvironment. This has important implications for the immunotherapy of patients with cancer. Specifically, HMGB1 may promote healing or immune reactivity, depending on the nature of the local inflammatory response and the presence (or absence) of immune effectors.

Key Words: lymphocytes • necrosis • granzyme • death receptor

This article has been cited by other articles:

				W. Jiang, C. W. Bell, and D. S. Pisetsky The Relationship between Apoptosis and High-Mobility Group Protein 1 Release from Murine Macrophages Stimulated with Lipopolysaccharide or Polyinosinic-Polycytidylic Acid J. Immunol., May 15, 2007; 178(10): 6495 - 6503. [Abstract] [Full Text] [PDF]

				M. E. Bianchi DAMPs, PAMPs and alarmins: all we need to know about danger J. Leukoc. Biol., January 1, 2007; 81(1): 1 - 5. [Abstract] [Full Text] [PDF]